Skip to Content

Flublok Approval History

FDA Approved: Yes (First approved January 16, 2013)
Brand name: Flublok
Generic name: influenza vaccine
Dosage form: Injection
Company: Protein Sciences Corp.
Treatment for: Influenza Prophylaxis

Flublok (influenza vaccine, recombinant hemagglutinin) is an influenza vaccine indicated for active immunization against seasonal influenza in adults 18 years of age and older .

Flublok is manufactured using modern cell culture technology, and does not contain any preservatives (e.g., thimerosal, which contains mercury), egg proteins, gelatin or latex.

Flublok is administered via intramuscular (IM) injection annually prior to flu season. The most commonly reported side effect is pain at the injection site. Headache, fatigue or muscle aches may also occur.

Development History and FDA Approval Process for Flublok

DateArticle
Oct 11, 2016Approval FDA Approves Flublok Quadrivalent Influenza Vaccine
Jun 23, 2016Approval FDA Approved Longer Shelf Life for the Game Changer, Flublok Influenza Vaccine
Oct 29, 2014Approval Flublok Influenza Vaccine Now Approved for Adults Ages 18 and Older
Jan 16, 2013Approval FDA Approves Flublok - New Seasonal Influenza Vaccine Made Using Novel Technology

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide